每经AI快讯，9月11日，济民健康（603222）(603222.SH)公告称，公司股票今日收盘再次涨停，换手率 达到16.96%，自2025年9月8日至11日，收盘价格累计涨幅达33.78%，近30个交易日涨幅与上证A指偏离 值累计达94.72%，剔除大盘和板块整体因素后的实际涨跌幅波动较大，多个交易日连续大涨大跌，股 票交易存在明显异常，后续可能随时有快速下跌风险。 ...

济民健康股票交易风险提示公告，公司股票今日收盘再次涨停，换手率达到16.96%，自2025年9月8日 至11日，收盘价格累计涨幅达33.78%，近30个交易日涨幅与上证A指偏离值累计达94.72%，剔除大盘和 板块整体因素后的实际涨跌幅波动较大，多个交易日连续大涨大跌，股票交易存在明显异常，后续可能 随时有快速下跌风险。 ...

Group 1 - Jimin Health has experienced a significant increase, with 6 consecutive trading limits reached in 12 days [1] - Shutai Shen has risen over 7%, indicating strong market interest [1] - Hot景生物 has seen an increase of over 5%, reflecting positive investor sentiment [1] Group 2 - Other companies such as Meidi Xi, Guangsheng Tang, and Borui Pharmaceutical have also shown upward trends in their stock prices [1]

Core Viewpoint - Jimin Health (603222) experienced a significant increase in stock price, reaching the daily limit, with a trading volume of 1.202 billion yuan and a fluctuation of 18.35% [1][2]. Trading Activity - The stock was listed on the trading board due to its daily fluctuation of 18.35%, with a total net purchase by brokerage seats amounting to 66.0795 million yuan [2]. - The top five brokerage seats accounted for a total transaction of 289 million yuan, with a buying amount of 178 million yuan and a selling amount of 111 million yuan, resulting in a net purchase of 66.0795 million yuan [2]. - The largest buying brokerage was Huafu Securities, with a purchase amount of 59.0385 million yuan, while the largest selling brokerage was CITIC Securities, with a selling amount of 46.6849 million yuan [2]. Stock Performance - Over the past six months, the stock has appeared on the trading board 13 times, with an average price increase of 2.92% the day after being listed and an average increase of 10.07% in the following five days [3]. - The stock saw a net inflow of 237 million yuan from major funds today, with a significant inflow of 263 million yuan from large orders, while smaller orders saw a net outflow of 25.9314 million yuan [3]. - In the past five days, the net inflow of major funds totaled 290 million yuan [3]. Financing and Margin Data - As of September 10, the stock's margin trading balance was 197 million yuan, with a financing balance of 197 million yuan and a securities lending balance of 115,000 yuan [3]. - In the past five days, the financing balance increased by 224,900 yuan, reflecting a growth rate of 0.11%, while the securities lending balance increased by 22,900 yuan, with a growth rate of 24.84% [3]. Financial Results - According to the semi-annual report released on August 21, the company achieved a revenue of 366 million yuan in the first half of the year, representing a year-on-year decline of 21.30%, and reported a net loss of 52.6959 million yuan [3].

Market Overview - The Shanghai Composite Index rose by 1.65% on September 11, with 31 out of 41 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.39% and 5.96% respectively [2] - The pharmaceutical and biotechnology sector saw a modest increase of 0.25% [2] Capital Flow Analysis - The net inflow of capital in the two markets reached 34.518 billion yuan, with 11 sectors experiencing net inflows [2] - The electronics sector had the highest net inflow of 21.723 billion yuan, corresponding to its 5.96% increase, followed by the computer sector with a net inflow of 8.479 billion yuan and a daily increase of 3.71% [2] Pharmaceutical and Biotechnology Sector Performance - Within the pharmaceutical and biotechnology sector, there were 474 stocks, with 350 stocks rising and 111 stocks declining [3] - The top three stocks with the highest net inflow were Jimin Health (2.37 billion yuan), Shutai Shen (1.55 billion yuan), and Rejing Bio (1.41 billion yuan) [3] - The sector experienced a net outflow of 3.975 billion yuan, with the largest outflows from WuXi AppTec (3.17 billion yuan), BeiGene (2.29 billion yuan), and Zhaoyan New Drug (1.78 billion yuan) [3][5] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +10.02% with a turnover rate of 16.96% and a capital flow of 236.996 million yuan - Shutai Shen: +7.24% with a turnover rate of 10.87% and a capital flow of 155.111 million yuan - Rejing Bio: +11.40% with a turnover rate of 6.65% and a capital flow of 140.912 million yuan [4] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - WuXi AppTec: -2.41% with a turnover rate of 4.06% and a capital outflow of -317.3795 million yuan - BeiGene: -3.73% with a turnover rate of 11.42% and a capital outflow of -229.1395 million yuan - Zhaoyan New Drug: -2.88% with a turnover rate of 9.44% and a capital outflow of -178.0592 million yuan [5]

Group 1 - The medical device ETF (562600) opened lower but closed up by 1.25%, with leading stocks such as Hotspring Bio rising by 11.40% and Jimin Health and Zhend Medical hitting a strong limit up of 10% [1] - The National Medical Products Administration (NMPA) has focused on key areas such as medical robots, high-end medical imaging, AI medical devices, and new biological materials, approving 52 innovative products this year, totaling 367 approved innovative products to date [1] - Recent high-level discussions emphasized principles like "anti-involution" and "optimizing centralized procurement without solely focusing on low prices," indicating a clear signal for policy shifts supporting the innovative medical device industry [1] Group 2 - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device sector, tracking the CSI All Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2] - The medical device sector accounts for a significant 89.34% of the index, indicating a concentrated focus on capturing the development dividends in this field [2] - As of the first quarter of 2025, the top ten holdings in the medical device ETF (562600) include Mindray Medical and United Imaging, which together account for 22.3% of the ETF [2]

Group 1 - The innovative drug concept stocks have shown signs of recovery, with Ji Min Health achieving a six-day consecutive increase [1] - Shu Tai Shen has risen over 7%, while Rejing Bio has increased by more than 5% [1] - Other stocks such as MediX, Guangsheng Tang, and Borui Pharmaceutical have also experienced upward movement [1]

Core Viewpoint - The stock of Jimin Health Management Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative closing price deviation exceeding 20% over three consecutive trading days, indicating potential market risks [2][5][9]. Group 1: Stock Trading Abnormalities - The company's stock price increased by a cumulative deviation of 75.32% over the past 30 trading days, suggesting significant volatility that diverges from the company's operational performance [2][9]. - The stock experienced a cumulative closing price deviation of over 20% on September 8, 9, and 10, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange rules [5][9]. Group 2: Company Verification and Response - The company conducted a self-examination and confirmed that there have been no significant changes in its main business or external operating environment, and no undisclosed major events exist [6][7]. - The controlling shareholder disclosed a share reduction plan on September 5, 2025, but no other major transactions or restructuring activities were reported [3][6]. Group 3: Financial Performance - For the first half of 2025, the company reported a net loss of 52.70 million yuan, a decline compared to the same period last year [9].

关于济民健康管理股份有限公司 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025年 9 月 10 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权,为公司实际控 制人。 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 双鸽集团有限公司 2×年9月/0日 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 本家族全体成员于 2025年9月10 ...

●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司控股股东于 2025 年 9 月 5 日披露了减持股份计划。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 证券代码：603222 证券简称：济民健康 公告编号：2025-045 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●公司股票交易于 2025 年 9 月 8 日、9 月 9 日、9 月 10 日连续三个交易日内 收盘价格涨幅偏离值累计超过 20%，属于《上海证券交易所交易规则》规定的股票 交易异常波动情形。公司股价近 30 个交易日涨幅偏离值累计达 75.32%，剔除大盘 和板块整体因素后的实际涨跌幅波动较大，存在异常交易情形，公司股价走势与 经营业绩趋势相偏离，敬请广大投资者注意二级市场交易风险，理性决策，审慎 投资。 （一）经公司自查，公司主营业务未发生重大变化，内外部经营环境未发生 ...